mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Approx 800 million Indians do not have health coverage, says Expert

Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand

Bridgewest Group launches new sterile injectable CDMO NovaCina

Dozee Raises $6 million to bolster its ambition of ‘HarBedDozeeBed’

Dozee plans to further tap over 2,000 hospitals in more than 100 districts

Biocon awarded Silver Medal by EcoVadis for sustainability accomplishments

For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)

Top management changes at IOL Chemicals and Pharmaceuticals

Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company

Antibody-drug conjugates gain traction in China oncology market, says GlobalData

China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets

EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company

EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging

Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer

Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations

ProBioGen delivers strong 2022 performance

ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.